Genvoya™

Read the CMI leaflet (Opens in new tab) for facts you need to know before, during and after taking your medicine.

For more information about CMIs and how to read them, please visit How to read Consumer Medicine Information (CMI).

GENVOYA is indicated as a single tablet regimen for the treatment of HIV-1 infection in adults and paediatric patients weighing at least 25 kg who are either treatmentnaïve; or virologically suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen at start of therapy in order to replace their current antiretroviral treatment regimen (see 5.1 Pharmacodynamic properties, Clinical Trials). Patients must not have a history of treatment failure or known mutations associated with resistance to the antiretroviral components of GENVOYA. GENVOYA is a fixed dose combination of one integrase inhibitor, one pharmacokinetic enhancer and two nucleos(t)ide HIV-1 reverse transcriptase inhibitors.

Source: ARTG

• Shelf lifetime is 24 Months
• Store below 25 degrees Celsius

Source: ARTG

Non-composite pack

This medicine contains one component only.

Component

• Tablet, film coated
• Oral
• Film-coated, capsule shaped and green in colour. Each tablet is debossed with 'GSI' on one side and the number "510" on the other side.

Source: ARTG

These medicine packs are available from a pharmacist and requires a prescription. It is Schedule 4: Prescription Only Medicine.?What is the medicines and poisons schedule?

All medicines and poisons in Australia are categorised by how they are made available to the public. Medicines with a low safety risk are usually less tightly controlled than medicines with a higher safety risk. This system is called ‘scheduling’. You can read more about the scheduling of medicines as well as the different scheduling categories on our Scheduling of medicines and poisons information page.

• 30 tablets

Source: ARTG

This medicine was verified as available on the Pharmaceutical Benefits Scheme (PBS) on 1 August 2026, under PBS item code 11114Y (Opens in new tab). Ask your pharmacist or doctor about your eligibility

Source: PBS

For the active ingredient: Tenofovir alafenamide + emtricitabine + elvitegravir + cobicistat

You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.

Source: AHT

If you experience a side effect from this medicine, tell your doctor or pharmacist. Or report it directly to the TGA (Therapeutic Goods Administration).

You can report side effects to your doctor, or directly at Report an adverse event or safety problem (Opens in new tab)

Source: ARTG

Healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions (Opens in new tab).